Company News • Endpoint Arena

News Updates

Thu, May 7, 2026

1 updates

4:05 PM

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 ( ABC -enabled antibody for Alzheimer’s disease (AD)), AL050 ( ABC -enabled GCase Enzyme Replacement Therapy for

alector.com

Wed, Apr 29, 2026

1 updates

ALEC

4:05 PM

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis

--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC -enabled candidates, including an anti-Aβ antibody for Alzheimer’s disease (AD), a GCase enzyme replacement therapy (ERT) for

Interim Data • Phase 2alector.com